? WOMEN?S CANCER PROGRAM The Duke Cancer Insitute?s Women?s Cancer Program (WC) is a multidisciplinary clinical, basic, and translational research effort whose overall goal is to improve outcomes for women with breast and gynecologic cancers. The broad, long-term goal of the WC Program is to build on and extend current knowledge in the field of breast and gynecological cancers and to develop novel strategies for improving therapeutic results. Significant progress has been made in identifying pathways of pathological importance in cancer and in validation of steps in these pathways as therapeutic targets. However, genetic heterogeneity among cancers, and the utilization of different growth and survival pathways by different tumor types, have made it difficult to realize the therapeutic potential of even the most tractable targets. Thus a central theme of the research being undertaken by members of the Women?s Cancer Program is biological study of breast and gynecological cancers and development of therapeutic strategies tailored to specific cancer subtypes. These efforts have led to identification of potential targets, the modulation of which are likely to selectively impact triple negative breast cancer, endocrine-resistant ER-positive breast cancers, inflammatory breast cancer, or gynecologic cancers. This successful strategy will be continued with efforts to: (a) Elucidate the biological basis of breast and gynecologic cancers with a focus on defining therapeutically actionable pathways and relevant biomarkers; (b) Develop and accrue to innovative clinical trials that build upon the scientific expertise of the program members; (c) Facilitate health services research that optimizes use of health care resources in a cost-effective manner while accounting for personal characteristics of individual patients such as genetic variation in risk and patient preferences; and (d) Provide structured mentoring and career development programs for junior faculty, postdoctoral fellows and students. Reflecting the breadth of the interests and expertise of its constituency, the Program?s activities establish, maintain, and strengthen infrastructure that fosters scientific interaction for research to generate novel strategies for the prevention, detection, and treatment of breast and gynecological cancers. The program is comprised of 29 primary members and 8 secondary members from 11 different departments and 4 schools within Duke University. Total direct funding for primary program members is $14.5M, of which $11.4M is peer reviewed, including $3.5M from the NCI. From 2014-2018, program members published 747 papers in peer-reviewed journals, 26% were intra-programmatic collaborations and 44% were inter-programmatic collaborations. During the current grant period, the program enrolled 2,829 subjects to all trials, 933 to interventional trials, and 342 to treatment trials.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Duke University
United States
Zip Code
Feng, Yun; Wang, Yanru; Liu, Hongliang et al. (2018) Novel genetic variants in the P38MAPK pathway gene ZAK and susceptibility to lung cancer. Mol Carcinog 57:216-224
Naqvi, Ibtehaj; Gunaratne, Ruwan; McDade, Jessica E et al. (2018) Polymer-Mediated Inhibition of Pro-invasive Nucleic Acid DAMPs and Microvesicles Limits Pancreatic Cancer Metastasis. Mol Ther 26:1020-1031
Wen, Juyi; Liu, Hongliang; Wang, Lili et al. (2018) Potentially Functional Variants of ATG16L2 Predict Radiation Pneumonitis and Outcomes in Patients with Non-Small Cell Lung Cancer after Definitive Radiotherapy. J Thorac Oncol 13:660-675
Li, Bo; Wang, Yanru; Xu, Yinghui et al. (2018) Genetic variants in RORA and DNMT1 associated with cutaneous melanoma survival. Int J Cancer 142:2303-2312
Gearhart-Serna, Larisa M; Jayasundara, Nishad; Tacam Jr, Moises et al. (2018) Assessing Cancer Risk Associated with Aquatic Polycyclic Aromatic Hydrocarbon Pollution Reveals Dietary Routes of Exposure and Vulnerable Populations. J Environ Public Health 2018:5610462
Bakthavatsalam, Subha; Sleeper, Mark L; Dharani, Azim et al. (2018) Leveraging ?-Glutamyl Transferase To Direct Cytotoxicity of Copper Dithiocarbamates against Prostate Cancer Cells. Angew Chem Int Ed Engl 57:12780-12784
Dai, Ziwei; Mentch, Samantha J; Gao, Xia et al. (2018) Methionine metabolism influences genomic architecture and gene expression through H3K4me3 peak width. Nat Commun 9:1955
Powell Gray, Bethany; Kelly, Linsley; Ahrens, Douglas P et al. (2018) Tunable cytotoxic aptamer-drug conjugates for the treatment of prostate cancer. Proc Natl Acad Sci U S A 115:4761-4766
Abdi, Khadar; Lai, Chun-Hsiang; Paez-Gonzalez, Patricia et al. (2018) Uncovering inherent cellular plasticity of multiciliated ependyma leading to ventricular wall transformation and hydrocephalus. Nat Commun 9:1655
Hudson, Kathryn E; Rizzieri, David; Thomas, Samantha M et al. (2018) Dose-intense chemoimmunotherapy plus radioimmunotherapy in high-risk diffuse large B-cell lymphoma and mantle cell lymphoma: a phase II study. Br J Haematol :

Showing the most recent 10 out of 513 publications